About this trial
The European Society for Dermatology \& Psychiatry (ESDaP) studies the connection between the skin and the mind. Two previous studies of this type were conducted in 13 and 15 European countries, respectively. The first study assessed the psychological impact of skin diseases (anxiety, depression, sleep disorders), and the second analyzed feelings of stigma, stress, and body dysmorphic disorder (an abnormal perception of one's body).
In this study, new psychological variables will be examined: coping strategies, loneliness, and resilience.
A total of 23 centers will participate in the ESDaP3 study, located in 15 European countries (Austria, France, Germany, Hungary, Italy, North Macedonia, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Turkey, and the United Kingdom).
The aim of this study is to examine coping strategies, loneliness, and resilience among patients with a skin condition. Coping strategies refer to the various ways a person uses to manage a difficult or stressful situation. Resilience refers to a person's ability to cope with difficult situations, adapt to changes or challenges, and regain a sense of balance despite obstacles. Other factors will be assessed: sleep, anxiety and depression, and quality of life. A questionnaire will be given to your potential partner to assess the impact of the skin condition on their life at this time.
At the study's sole French site, Brest University Hospital, 250 patients with a skin condition and 125 people without a skin condition will be enrolled.
Eligibility criteria
Qualifiers
Patients with skin conditions (inflammatory, autoimmune, cancerous, or genetic skin disorders)
Controls: individuals without skin disease
Adult participant
Participant enrolled in a Social Security system or equivalent
Disqualifiers
Participants who are unable to understand the protocol
Participants under legal guardianship (guardianship, conservatorship)
Participants subject to a future protection order, family authorization, or court-ordered protection
Participants who are unable to complete the questionnaires
Trial design
Treatments tested in this trial
- Questionnaires
Treatment groups
Sponsors and collaborators
University Hospital, Brest
Lead sponsor
University of Graz
Collaborator
Justus-Liebig University Gießen Medical Center
Collaborator
Szeged University
Collaborator
University of Skopje
Collaborator
University of Amsterdam
Collaborator
University of Stavanger
Collaborator
University of Bergen
Collaborator
Wroclaw Medical University
Collaborator
University of Rzeszow
Collaborator
Universidade do Algarve
Collaborator
Universidad de Zaragoza
Collaborator
University of La Laguna
Collaborator
Malmö University
Collaborator
Lund University
Collaborator
Karolinska Institutet
Collaborator
Sisli Hamidiye Etfal Training and Research Hospital
Collaborator
Cardiff University
Collaborator
University Hospital Muenster
Collaborator
Leiden University Medical Center
Collaborator
The Royal London Hospital, UK
Collaborator